Charles River Labs to Acquire HemaCare for $380M, Expanding Presence in Cell Therapy

Charles River Laboratories has agreed to acquire HemaCare for $380 million, in a deal designed to expand the buyer’s capabilities by offering cell therapy developers and manufacturers a solution taking them from basic research through commercialization.

Read the full article here

Related Articles